AstraZeneca filed a legal petition after the pricing authority issued a notice accusing the firm of overcharging for its asthma inhaler formulation. The regulator claimed the overpricing took place during a period spanning from May 2016 through November 2025. In response, AstraZeneca denied all allegations that it sold the medication above mandated limits. The court has now demanded an official reply from the pricing regulator ahead of the January 11 proceedings.
Key points
AstraZeneca successfully established a prima facie case that its medication might not fal…: AstraZeneca successfully established a prima facie case that its medication might not fall under statutory price controls.
The targeted medicine treats asthma using a combination of a corticosteroid and a long-ac…: The targeted medicine treats asthma using a combination of a corticosteroid and a long-acting beta-agonist.
The pricing authority must file a formal response addressing the pharmaceutical company's…: The pricing authority must file a formal response addressing the pharmaceutical company's petition before the next court date.
Sources checked by our analysis pipeline: 1
The court order will be in effect till January 11, the next date of hearing.
AstraZeneca Pharma has made out a prima facie case that its Symbicort Turbuhaler 160/4.5 (Inhaler) may not fall within the category of drugs whose prices are controlled under the Drugs (Price Control) Order, 2013, said Justice Amit Mahajan, while seeking the pricing authority's response on the pharma company's petition related to pricing violations under the Drugs (Price Control) Order, 2013.
AstraZeneca Pharma's Symbicort Turbuhaler 160/4.5 is used in the treatment of asthma where the use of a corticosteroid and long-acting beta-agonist combination is appropriate. The authority had issued a notice to the company, alleging that it was overcharging for the inhaler. The NPPA claimed violations occurred during the period May 2016 to November 2025.
The company has denied allegations that it sold the product at a price higher than that fixed for such formulations.
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
Subscribe to The Economic Times Prime and read the ET ePaper online.
Strong quarterly demand for flagship hardware helped the tech giant surpass market expectations despite persistent headwinds in other consumer categories. Robust sales of personal computers and handsets offset simultaneous pullbacks in connected lifestyle devices and tablets. The performance underscores how central core product lines remain in insulating overall hardware earnings.
Financial analysts had set conservative targets ahead of the release of the technology firm's quarterly figures. Strong consumer demand across international hardware markets propelled the company past those benchmark estimates. The performance signals sustained momentum across the technology giant's flagship product ecosystem despite broader market uncertainty.
The technology giant exceeded Wall Street expectations across top and bottom lines during the recent financial quarter. These quarterly gains establish strong momentum during a notable leadership shift for the firm. Investors closely watched the transition as the executive team delivered double-digit growth.